Susquehanna International Group’s Jasper Therapeutics JSPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-34,600
Closed -$63.3K 13642
2025
Q4
$63.3K Buy
34,600
+8,500
+33% +$17.1K ﹤0.01% 11668
2025
Q3
$62.1K Sell
26,100
-2,100
-7% -$6.37K ﹤0.01% 11790
2025
Q2
$157K Buy
28,200
+4,500
+19% +$22.2K ﹤0.01% 11467
2025
Q1
$102K Sell
23,700
-20,600
-47% -$137K ﹤0.01% 11531
2024
Q4
$947K Sell
44,300
-42,900
-49% -$893K ﹤0.01% 7100
2024
Q3
$1.64M Sell
87,200
-26,200
-23% -$522K ﹤0.01% 5706
2024
Q2
$2.57M Buy
113,400
+13,200
+13% +$317K ﹤0.01% 4596
2024
Q1
$2.94M Buy
+100,200
New +$1.78M ﹤0.01% 4560
2023
Q3
Sell
-6,250
Closed -$85.6K 12485
2023
Q2
$85.6K Sell
6,250
-950
-13% -$14.1K ﹤0.01% 11062
2023
Q1
$130K Buy
+7,200
New +$133K ﹤0.01% 11048
2022
Q3
Sell
-2,480
Closed -$48K 13676
2022
Q2
$48K Sell
2,480
-17,090
-87% -$487K ﹤0.01% 11993
2022
Q1
$695K Sell
19,570
-3,670
-16% -$165K ﹤0.01% 8104
2021
Q4
$1.82M Buy
+23,240
New +$2.17M ﹤0.01% 5731

Other funds holding JSPR

Susquehanna International Group's JSPR Position: Q1 2026 in Review

Susquehanna International Group reduced its Jasper Therapeutics (JSPR) stake by 89% in Q1 2026, selling an estimated $130K and leaving 11,149 shares worth $9.77K. The position accounts for ﹤0.01% of the portfolio, ranked #12942.

Susquehanna International Group first reported a position in JSPR in Q4 2022 and has held it in 10 quarters since. The position peaked at $488K in Q4 2024. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

  • Susquehanna International Group held 11,149 shares of Jasper Therapeutics worth $9.77K as of Q1 2026.
  • Susquehanna International Group sold 93,638 Jasper Therapeutics shares in Q1 2026, an estimated $130K.
  • Jasper Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12942 holding.
  • Susquehanna International Group first reported a position in Jasper Therapeutics in Q4 2022 and has held it in 10 quarters since.
  • Susquehanna International Group's Jasper Therapeutics position peaked at $488K in Q4 2024.
  • 58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.